| Literature DB >> 35711771 |
Sinjini Patra1, Nilanjan Sahu2, Shivam Saxena1, Biswaranjan Pradhan3, Saroj Kumar Nayak3, Anasuya Roychowdhury1.
Abstract
Background: Dysbiosis/imbalance in the gut microbial composition triggers chronic inflammation and promotes colorectal cancer (CRC). Modulation of the gut microbiome by the administration of probiotics is a promising strategy to reduce carcinogenic inflammation. However, the mechanism remains unclear.Entities:
Keywords: bacteriocins; colorectal cancer; gene network analysis; gut microbiome; meta-analysis; molecular docking; probiotic intervention; systematic review
Year: 2022 PMID: 35711771 PMCID: PMC9195627 DOI: 10.3389/fmicb.2022.878297
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Figure 1The search and selection process for the systematic review. The PRISMA diagram represents the method for literature search and selection.
Figure 2Meta-analysis study justifies the efficacy of the probiotic intervention in the treatment and prevention of CRC-promoting gut inflammation. The Forest plot shows 95% confidence intervals and pooled mean difference to evaluate the result of placebo controls vs. probiotics-based treatment (after heterogeneity adjustment) on patients with CRC (A). The Funnel plot of the effect size plotted with the standard error examines publication bias to show the effect of probiotics on CRC in various clinical trials (B). The pooled effect size is represented by the perpendicular line to the x-axis. Positive or negative bias is represented by the studies outside the triangle. Thus, the substantial asymmetry in the funnel plot signifies the absence of publication bias.
Probiotics or probiotic formulations, applied in prevention and treatment of colorectal cancer (CRC) in human clinical trials.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Bajramagic et al. ( |
|
| Adults (patients with colorectal adenocarcinoma) | 2 ×1 capsules from the third post-operative day during the next thirty days, and then 1 ×1 for two weeks each next month to a total of one year | Oral | Significantly reduced post-operative complications in the localization of tumors on the rectum and the ascending colon |
| Delia et al. ( |
| Adults (Cancer patients) | 1 sachet of VSL#3 with 450 billion/g of viable lyophilized bacteria starting from the first day of radiation therapy until the end of the scheduled cycles of radiation therapy | Oral | Protected cancer patients against the risk of radiation-induced diarrhea | |
| Flesch et al. ( |
| Adults 60 −65 years (patients with colorectal cancer) | 2 sachets each with 1 ×10 | Oral | Significantly reduced post-operative infection rates in patients with colorectal cancer | |
| Hatakka et al. ( |
| Adults 24–55 years (healthy) | 1 capsule containing viable 2 ×1010 cfu of each strain LC705 and PJS daily for 4 weeks | Oral | Increased the fecal counts of | |
| Ishikawa et al. ( |
| Adults 40–65 years (cancer patients) | 1 g powder with 1 ×1010 cfu viable cells after every meal for 4 years after removal of colorectal tumor | Oral | Suppressed the development of colorectal tumors | |
| Kotzampassi et al. ( |
| Adults ≥18 years (patients diagnosed with colorectal cancer programmed for open surgery for colorectal cancer) | 1 capsule with 1.75 ×109 cfu | Oral | Significantly decreased the risk of post-operative complications, like mechanical ventilation, infections, and anastomotic leakage in colorectal cancer patients | |
| Liu and Huang ( |
|
| Adults 50–70 years (cancer patients) | 4 B. tetragenous viable bacteria tablets (Siliankang®), 3 times per day and continued for 4 weeks as one cycle | Oral | Effective for treating cancer patients with functional constipation, and is safe and well-tolerated |
| Odamaki et al. ( |
| Adults 30–50 years (healthy) | Yogurt with 1.0 ×109 cfu lactic acid bacteria, 4.27 ×108, and more than 1.25 ×108 cfu living | Oral | Eliminated enterotoxigenic Bacteroides fragilis (ETBF) strains in the microbiota, associated with acute and persistent diarrheal disease, inflammatory bowel disease, and colorectal cancer | |
| Osterlund et al. ( |
| Adults 31–75 years (cancer patients) | 1 gelatine capsule with 1–2 ×1010 cfu | Oral | Reduced the frequency of severe 5-FU-based chemotherapy-related diarrhea | |
| Polakowski et al. ( |
| Adults 51–68 years (cancer patients) | 100 ml of water with Simbiflora containing 6 g of fructo-oligosaccharide and 1 ×109 cfu each of | Oral | Reduced levels of pro-inflammatory C-reactive protein, IL6, antibiotic use and length of hospital stay after surgery, and morbidity in colorectal cancer patients in the post-operative period. | |
| Rafter et al. ( |
| Adults 46–68 years (cancer patients) | 1 ×1010 cfu/g product daily for 12 weeks after resection of colon cancer | Oral | Increased | |
| Roller et al. ( |
| Adults 54–68 years (cancer patients) | 1 sachet with 1 ×1010 cfu | Oral | Prevented increase in IL-2 secretion by activated PBMC, increased capacity of PBMC to produce IFN-γ | |
| Scartoni et al. ( |
| Adults >18 years candidates to receive radiation therapy (radical or neo/adjuvant) for colorectal, cervical, anal, endometrial, and prostate cancer | 1 ×10 ml vial, Dixentil (Gamfarma srl, Milano Italy) with 500 mg of galacto-oligosaccharides, 10 mg | Oral | Prevented and reduced radiation-related or radiation-induced gastrointestinal disorders in colorectal cancer patients | |
| Zaharuddin et al. ( |
| Adults ≥18 years (patients diagnosed with colorectal cancer) | 107 mg of probiotics with 30 ×109 cfu of six viable | Oral | Reduced systemic production of pro inflammatory cytokines, TNF-α, IL-17A, IL-17C, IL-22, IL-10, and IL-12 and prevented post-surgical complications in colorectal cancer patients | |
| Zhang et al. ( |
| Adult 45–90 years (patients diagnosed with colorectal adenocarcinoma and elective radical CRC resection with laparotomy) | Bifid triple viable capsule, each with 0.21 g (108 cfu/g) | Oral | Maintained the intestinal flora, restricted bacterial translocation from the intestine minimized the post-operative occurrence of infectious complications, enhanced systemic/localized immunity and attenuated systemic stress response |
Identified probiotic strains and the corresponding training gene sets associated with CRC-triggering gut inflammation.
|
|
|
|
|---|---|---|
| Cruz et al. ( | ||
| Roller et al. ( |
| |
| Kaeid Sharaf and Shukla ( |
| |
| Mahkonen et al. ( |
| |
| Deol et al. ( |
| |
| Oh et al. ( |
| |
| Walia et al. ( |
| |
| Sharifi et al. ( |
|
|
| Madempudi and Kalle ( |
| |
| Irecta-Nájera et al. ( |
| |
| Huang et al. ( |
| |
| Daniluk et al. ( |
|
|
| Karimi Ardestani et al. ( |
| |
| Talero et al. ( |
| |
| Chen et al. ( |
| |
| Lan et al. ( |
| |
| Femia et al. ( |
| |
| Parisa et al. ( |
|
|
| Oh et al. ( |
| |
| Agah et al. ( |
| |
| An et al. ( |
| |
| An and Ha ( |
|
|
|
| ||
| Bassaganya-Riera et al. ( |
|
|
| Bertkova et al. ( |
|
|
| Borowicki et al. ( |
| |
| Chen et al. ( |
| |
| Chen et al. ( |
| |
| Chen et al. ( |
| |
| Chondrou et al. ( |
| |
| Chung et al. ( | VSL#3: |
|
| Chung et al. ( |
| |
| Cousin et al. ( |
| |
| Del Carmen et al. ( |
| |
| Djaldetti and Bessler ( |
|
|
| Ewaschuk et al. ( |
| |
| Fahmy et al. ( |
| |
| Foo et al. ( |
| |
| Gamallat et al. ( |
| |
| Golkhalkhali et al. ( |
| |
| Hadad et al. ( |
|
|
| Heydari et al. ( |
| |
| Ko et al. ( |
| |
| Konishi et al. ( |
| |
| Kuugbee et al. ( |
|
|
| Liu et al. ( |
| |
| Ma et al. ( |
|
|
| Mendes et al. ( |
|
|
| Mi et al. ( |
|
|
| Norouzi et al. ( |
| |
| Rong et al. ( | ||
| Song et al. ( |
|
|
| Lee et al. ( |
|
|
| Do et al. ( | VSL#3: |
|
| Yue et al. ( |
| |
| Kim et al. ( |
| |
| Dong et al. ( |
| |
| Tiptiri-Kourpeti et al. ( |
| |
| Walia et al. ( |
| |
| Chen et al. ( | ||
| Saito et al. ( |
|
Figure 3Network topologies of the significant MCODE clusters. MCODE-derived cluster 1: score 11.2, nodes 21 (mapk14, jun, stat3, mapk8, mapk9, mapk3, myc, ets2, rin1, akt1, atg5, atg7, atg12, atg3, banf1, atg16l1, atg4c, atic, aprt, acaca, and prkaa1), and edges 112 (A). MCODE-derived cluster 2: score 8.894, nodes 48 (gli2, myd88, wdtc1, tlr4, ang, nos2, agtr1, mlkl, fadd, sqstm1, ripk3, becn1, mfn2, bcl2l1, loc728519, alpi, diablo, birc2, xiap, bcl2, bax, mmp2, mmp9, col1a1, col1a2, ogn, prelp, mmp1, mmp3, mmp12, frap1, pik3ca, ifi27, hspg2, soat1, bbc3, tp53, cdkn1a, mdm2, pmaip1, ddit3, runx1, atf4, pp1r15a, slc12a3, rictor, id2, and tsc2), and edges 209 (B). MCODE-derived cluster 3: score 7, nodes 7 (atp5b, pdk4, atp8a2, cycs, acadm, 1.2.2.2, and 3.6.3.14), and edges 21 (C). MCODE-derived cluster 4: score 5, nodes 5 (smad7, pten, dgcr5, mirn21, and mirn23a), and edges 10 (D). MCODE-derived cluster 7: score 4.48, nodes 26 (il1b, il6, tnf, il10, ifng, atn1, nod2, nod1, clec7a, clec4e, stat5a, parp1, mcl1, ervk2, erbb2, erbb3, egfr, hdac1, ephb2, ros1, sod1, ppa1, dynamin, igfals, tardbp, and cmp1), and edges 56 (E). MCODE-derived cluster 8: score 4, nodes 7 (ccr1, ccr5, atgr2, il8, csf2, cxcl1, and ccl5), and edges 12 (F).
Figure 4Interaction of CRC-associated proteins and probiotic-derived bacteriocins. COX-2 with Plantaricin JLA-9 (A). COX-2 with lactococcin A (B). CASP9 with Lactococcin mmfii (C). CASP9 with Plantaricin JLA-9 (D). PI3K with Lactococcin mmfii (E). PI3K with Plantaricin W (F). IL18R with Plantaricin JLA-9 (G). IL18R with Lactococcin mmfii (H).
Interaction of bacteriocins with COX-2, CASP9, PI3K, and IL18R by molecular docking.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Plantaricin JLA-9 | ||||
| Lactococcin A | ||||
| Lactococcin mmfii | ||||
| Plantaricin | ||||
| Bacteriocin 28b | ||||
| Plantaricin D | ||||
| Plantaricin BN | ||||
Figure 5The mechanistic model of the consequences of probiotic application to prevent colorectal cancer promoting gut inflammation. Probiotics strengthen the protective epithelial barrier that prevents the entry of toxic metabolites due to leaky gut (i). Probiotics colonize the epithelial barrier and re-establish the gut equilibrium by producing antimicrobial peptides (AMPs), bacteriocins, and SCFAs that regulate metabolic processes (ii). Probiotics decrease nitric oxide (NO) production and maintain cellular oxidative balance (iii). Probiotics downregulate NLRP3-mediated inflammatory processes (iv), stress-induced MAPK (v), and NF-κB pathways (vi). Probiotics balance host immunity by stimulating anti-inflammatory cytokines and suppressing pro-inflammatory cytokines (vii) and inhibiting COX-2 production (viii). Probiotics downregulate PI3K/AKT and induce autophagy (ix) and apoptotic pathways (x) in CRC.